Uemura, Osamu
Ishikura, Kenji
Kamei, Koichi
Hamada, Riku
Yamamoto, Masaki
Gotoh, Yoshimitsu
Fujita, Naoya
Sakai, Tomoyuki
Sano, Takafumi
Fushimi, Masahiko
Iijima, Kazumoto
Clinical trials referenced in this document:
Documents that mention this clinical trial
Comparison of inulin clearance with 2-h creatinine clearance in Japanese pediatric patients with renal disease: open-label phase 3 study of inulin
https://doi.org/10.1007/s10157-021-02133-5
Article History
Received: 7 June 2021
Accepted: 6 September 2021
First Online: 25 September 2021
Declarations
:
: OU has received consultant fees from Fuji Yakuhin Co., Ltd., the manufacturer of inulin. The other authors have declared that no conflict of interest exists.
: The study was conducted according to Good Clinical Practice guidelines, the Declaration of Helsinki and other applicable regulatory requirements. The institutional review board at each institution approved the conduct of the study and clinical study protocol, informed consent form, investigator’s brochures, and other documents. The study information has been registered with the U.S National Library of Medicine (ClinicalTrials.gov Identifier: NCT03345316).
: Informed consent was obtained from all individual participants included in the study.